| abstract |
A pharmaceutical composition comprising a combination of (i) netupitant or a pharmaceutically acceptable salt thereof, (ii) a 5-HT3 antagonist or a pharmaceutically acceptable salt thereof, (iii) and dexamethasone, in which: a) said Netupitant or a pharmaceutically acceptable salt thereof is present in a therapeutically effective amount that is effective for treating nausea and vomiting during the acute and late stages of emesis and that enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK1 receptors in the striatum seventy-two hours after said administration; b) the 5-HT3 antagonist or a pharmaceutically acceptable salt thereof is administered in a therapeutically effective amount, which is effective for treating nausea and vomiting during the acute and late phases; and c) dexamethasone is present in a first dose that is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant, in which the first dose comprises 50 to 70% of a Minimum effective dose when administered alone. |